Shots:
- The P-III PACIFIC trial involves assessing Imfinzi vs PBO in 713 patients with unresectable, stage III NSCLC whose disease had not progressed following concurrent platinum-based CRT in 235 centers across 26 countries
- The updated post-hoc analyses demonstrated OS @5yrs. (42.9% vs 33.4%), m-OS (47.5 vs 29.1mos); at the treatment course of one year patients had not progressed after 5yrs. (33.1% vs 19%) respectively. The results were presented at ASCO 2021
- The therapy is approved for the treatment of ES-SCLC based on the P-III CASPIAN trial in the EU, US, Japan, and other countries globally and approved for previously treated patients with advanced bladder cancer in several countries
Click here to read full press release/ article | Ref: Business Wire | Image: Business Standard
The post AstraZeneca Reports Updated Results of Imfinzi (durvalumab) in P-III PACIFIC Trial for Non-Small Cell Lung Cancer first appeared on PharmaShots.
